Effect of acellular pertussis vaccine against various strains of Bordetella pertussis in a murine model of respiratory infection

Journal of Health Science

Volumn 48, Issue 6, 2002, Pages 560-564

  Watanabe, Mineo ^a   Nagai, Masaaki ^b  

^a DAIICHI UNIVERSITY OF PHARMACY   (Japan)

^b KITASATO INSTITUTE   (Japan)

Author keywords

Acellular pertussis vaccine; Aerosol challenge model; Bordetella pertussis; DPT vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; PERTUSSIS VACCINE;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL CELL; BACTERIAL STRAIN; BACTERIUM ISOLATE; BORDETELLA PERTUSSIS; CONTROLLED STUDY; DRUG EFFECT; FEMALE; LUNG; MODEL; MOUSE; NONHUMAN; PERTUSSIS; RESPIRATORY TRACT INFECTION;

ANIMALIA; BORDETELLA PERTUSSIS; MURINAE;

EID: 24944556773     PISSN: 13449702     EISSN: None     Source Type: Journal    
DOI: 10.1248/jhs.48.560     Document Type: Article

References (24)

1. Kasuga, T. (1970) Immunology of pertussis. Keio Igaku, 47, 607-627.
2. Kimura, M. and Kuno-Sakai, H. (1988) Epidemiology of pertussis in Japan. Tokai J. Exp. Clin. Med., 13 suppl., 1-7.
3. Ministry of Health, Labour and Welfare. (1999) Cases and Rates of SDCD and NCD, 1947-1998. In Statistics on Communicable Diseases in Japan 1998, 1999 (Jan.-Mar.) (Statistics and Information Department, Minister's Secretariat, Eds.), Statistics and Information Department, Tokyo, pp. 42-43.
4. Sato, Y. and Sato, H. (1988) Further characterization of Japanese acellular pertussis vaccine prepared in 1988 by six Japanese manufacturers. Tokai J. Exp. Clin. Med., 13 Suppl., 79-88.
5. Sato, H. (1997) Japanese experience with 60 million doses of acellular pertussis vaccines. Dev. Biol. Stand., 89, 327-329.
6. AL. In Bergey's Manual of Systematic Bacteriology, vol. 1 (Krieg, N. R. and Holt, J. G., Eds.) Williams & Wilkins, Baltimore, MD, pp. 388-393.
7. Kendrick, P. L., Eldering, G., Dixon, M. K. and Misner, J. (1947) Mouse protection tests in the study of pertussis vaccine: a comparative series using the intracerebral route of challenge. Am. J. Public. Health, 37, 803-810.
8. Association of Biologicals Manufacturers of Japan (1993) Adsorbed purified pertussis vaccine. In Minimum Requirements for Biological Products (Ministry of Health and Welfare, Eds), Association of Biologicals Manufacturers of Japan, Tokyo, pp. 143-146.
9. Xing, D. K. L., Das, R. G., Williams, L., Canthaboo, C., Tremmil, J. and Corbel, M. J. (1999) An aerosol challenge model of Bordetella pertussis infection as a potential bioassay for acellular pertussis vaccines. Vaccine, 17, 565-576.
10. Canthaboo, C., Xing, D. K. L., Douglas, A. and Corbel, M. (2000) Investigation of an aerosol challenge model as alternative to the intracerebral mouse protection test for potency assay of whole cell pertussis vaccines. Biologicals, 28, 241-246.
11. Watanabe, M., Komatsu, E., Abe, K., Iyama, S., Sato, T. and Nagai, M. (2002) Efficacy of pertussis components in an acellular vaccine, as assessed in a murine model of respiratory infection and a murine intracerebral challenge model. Vaccine, 20, 1429-1434.
12. Guiso, N., Capiau, C., Carletti, G., Poolman, J. and Hauser, P. (1999) Intranasal murine model of Bordetella pertussis infection. I. Prediction of protection in human infants by acellular vaccines. Vaccine, 17, 2366-2376.
13. Bruss, J. B. and Siber, G. R. (1999) Protective effects of pertussis immunoglobulin (P-IGIV) in the aerosol challenge model. Clin. Diagn. Lab. Immunol., 6, 464-470.
14. Mills, K. H. G., Ryan, M., Ryan, E. and Mahon, B. P. (1998) A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect. Immun., 66, 594-602.
15. van den Berg, B. M., David, S., Beekhuizen, H., Mooi, F. R. and van Furth, R. (2001) Protection and humoral immune responses against Bordetella pertussis infection in mice immunized with acellular or cellular pertussis immunogens. Vaccine, 19, 1118-1128.
16. Watanabe, M., Izumiya, K., Sato, T., Yoshino, K., Nakagawa, N., Ohoishi, M. and Hoshino, M. (1991) Comparative biological activity of acellular pertussis vaccines produced by the Kitasato Institute. Kitasato Arch. Exp. Med., 64, 31-42.
17. Endoh, M., Takezawa, T. and Nakase, Y. (1980) Adenylate cyclase activity of Bordetella organisms. I. Its production in liquid medium. Microbiol. Immunol., 24, 95-104.
18. Kasuga, T., Nakase, N., Ukishima, K. and Takatsu, K. (1954) Studies on Haemophilus pertussis. Part V. Relation between the phase of bacilli and the progress of the whooping-cough. Kitasato Arch. Exp. Med., 27, 57-62.
19. Watanabe, M., Nagai, M., Funaishi, K. and Endoh, M. (2001) Efficacy of chemical cross-linked antigens for acellular pertussis vaccine. Vaccine, 19, 1199-1203.
20. Watanabe, M., Funaishi, K., Takeo, T. and Endoh, M. (2001) Efficacy of pertussis vaccines consisted of antigens detoxified with tea-leaf catechines. Vaccine, 19, 1204-1210.
21. Watanabe, M., Komatsu, E., Sato, T. and Nagai, M. (2002) Differing protective effects of acellular pertussis vaccines in neonatal and young mice in a murine model of respiratory infection. J. Health Sci., 48, 341-345.
22. Guiso, N., Boursaux-Eude, C., Weber, C., Hausman, S. Z., Sato, H., Iwaki, M., Kamachi, K., Konda, T. and Burns, D. L. (2001) Analysis of Bordetella pertussis isolates collected in Japan before and after introduction of acellular pertussis vaccines. Vaccine, 19, 3248-3252.
23. Boursaux-Eude, C., Thiberge, S., Carletti, G. and Guiso, N. (1999) Intranasal murine model of Bordetella pertussis infection II. Sequence variation and protection induced by a tricomponent acellular vaccine. Vaccine, 17, 2651-2660.
24. Weber, C., Boursaux-Eude, C., Coralie, G., Caro, V. and Guiso, N. (2001) Polymorphism of Bordetella isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years. J. Clin. Microbiol., 39, 4396-4403.